{{Rsnum
|rsid=12208357
|Gene=SLC22A1
|Chromosome=6
|position=160122116
|Orientation=plus
|GMAF=0.02617
|Gene_s=LOC100289162,SLC22A1
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{PMID Auto
|PMID=19591196
|Title=Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver
}}

{{PharmGKB
|RSID=rs12208357
|Name_s=SLC22A1: R61C
|Gene_s=SLC22A1
|Feature=Exon/NonSyn
|Evidence=PubMed ID:19940846
|Annotation=Reduced metformin and MPP+ uptake in transfected cells
|Drugs=metformin; MPP+
|Drug Classes=
|Diseases=
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA165111556
}}

{{PharmGKB
|RSID=rs12208357
|Name_s=SLC22A1:148C>T (R61C)
|Gene_s=SLC22A1
|Feature=Exon/NonSyn
|Evidence=PubMed ID:17609683
|Annotation=SNP contributes to variation in the pharmacokinetics of metformin.
|Drugs=metformin
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA161149219
}}

{{GET Evidence
|gene=SLC22A1
|aa_change=Arg61Cys
|aa_change_short=R61C
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs12208357
|overall_frequency_n=615
|overall_frequency_d=10758
|overall_frequency=0.0571668
|n_genomes=3
|n_genomes_annotated=0
|n_haplomes=3
|n_articles=2
|n_articles_annotated=2
|in_pharmgkb=Y
|pph2_score=1.0
|nblosum100=8
|autoscore=3
|webscore=N
|n_web_uneval=10
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}